Route-specific human evidence is too limited to establish a preferred treatment.
Bottom line: No controlled human trial cited here compares oral with injectable BPC-157. The sources also do not provide a proven treatment protocol for either route. [1–3]
| BPC-157: Oral | Injectable | |
|---|---|---|
| Human evidence | The references here do not establish oral efficacy. [1–3] | Small uncontrolled joint-injection and intravenous reports. [1,2] |
| Absorption | A reliable human oral bioavailability percentage is not established by these sources. | The studies used different routes, including intravenous, intra-articular and subcutaneous administration. Their results are not interchangeable. |
| Dose | No validated routine treatment dose in these sources. | No validated routine subcutaneous injury-treatment dose in these sources. [1,2] |
| Gut versus injury claims | These sources do not establish oral BPC-157 as a treatment for gastrointestinal disease. | These sources do not establish that injecting near an injury improves healing. [1,2] |
tierA: {"tier":1,"label":"Treatment evidence not established"}
tierB: {"tier":1,"label":"Small uncontrolled human reports"}
summary: The cited human reports used joint injections or intravenous infusion. Neither establishes the effects of oral BPC-157 or injections into nearby subcutaneous tissue. [1,2]
trials: [{"name":"Retrospective knee-pain report","peptide":"b","n":"16 contacted","finding":"Joint injections; 12 received BPC-157 alone and four BPC-157 with TB4. No control group or standardized functional assessment.","pmid":"34324435"},{"name":"Intravenous pilot","peptide":"b","n":"2","finding":"Limited safety observations in two people cannot establish general or long-term safety.","pmid":"40131143"}]
The cited evidence does not support a reliable safety comparison between routes. Avoiding an injection does not itself establish a medicine's safety. [1–3]
No. The knee report concerns injections into a joint, not nearby subcutaneous tissue. The intravenous pilot used a different route again. [1,2]
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
